Literature DB >> 7686566

Vimentin expression in benign and malignant breast epithelium.

M Heatley1, C Whiteside, P Maxwell, P Toner.   

Abstract

AIMS: To determine vimentin expression in epithelial cells in benign breast disease and malignant breast tumours; to assess the value of vimentin expression as a prognostic indicator in breast carcinoma.
METHODS: Frozen and formalin fixed, paraffin wax embedded sections from 78 carcinomas, three phyllodes tumours, 19 fibroadenomas and 19 cases of fibrocystic disease were examined with a monoclonal antibody from the V9 clone. A correlation between vimentin expression and known prognostic indicators was sought in ductal carcinomas. The intracellular localisation of vimentin was examined in benign and malignant lesions.
RESULTS: Vimentin expression was identified on frozen section in the cells of ductal (53%), lobular (86%), and mucinous (33%) carcinomas and in the luminal epithelium of fibroadenomas (68%), cases of fibrocystic disease (47%), and a malignant phyllodes tumour. Formalin fixation reduced the percentage of carcinomas and cases of benign disease in which vimentin was detected. This reduction was more pronounced in fibroadenoma and fibrocystic disease than in ductal carcinoma. Associations were identified between vimentin expression as detected on frozen section and tumour grade, size, number of lymph nodes affected, oestrogen receptor content and growth fraction. Only the association with grade was significant (p = 0.045). There was no significant correlation between any of these prognostic variables and vimentin expression on paraffin wax sections. There was no difference in the intracellular localisation of vimentin staining between benign and malignant lesions, or between low and high grade ductal carcinomas.
CONCLUSION: There is some loss of vimentin immunoreactivity after formalin fixation. Vimentin expression does not assist in differentiating between benign and malignant breast disease, but is correlated with tumour grade in ductal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686566      PMCID: PMC501254          DOI: 10.1136/jcp.46.5.441

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  27 in total

1.  Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium.

Authors:  A S Leong; P Gilham; J Milios
Journal:  Histopathology       Date:  1988-10       Impact factor: 5.087

2.  Co-expression of cytokeratin and vimentin intermediate filament proteins in benign and neoplastic breast epithelium.

Authors:  W A Raymond; A S Leong
Journal:  J Pathol       Date:  1989-04       Impact factor: 7.996

3.  Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells.

Authors:  C L Sommers; D Walker-Jones; S E Heckford; P Worland; E Valverius; R Clark; F McCormick; M Stampfer; S Abularach; E P Gelmann
Journal:  Cancer Res       Date:  1989-08-01       Impact factor: 12.701

4.  Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas.

Authors:  W Domagala; L Woźniak; J Lasota; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

5.  Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction.

Authors:  W Domagala; J Lasota; J Bartkowiak; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

6.  Coexpression patterns of vimentin and glial filament protein with cytokeratins in the normal, hyperplastic, and neoplastic breast.

Authors:  V E Gould; G K Koukoulis; D S Jansson; R B Nagle; W W Franke; R Moll
Journal:  Am J Pathol       Date:  1990-11       Impact factor: 4.307

7.  Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas.

Authors:  W Domagala; J Lasota; A Dukowicz; M Markiewski; G Striker; K Weber; M Osborn
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

8.  Vimentin--a new prognostic parameter in breast carcinoma?

Authors:  W A Raymond; A S Leong
Journal:  J Pathol       Date:  1989-06       Impact factor: 7.996

9.  Regulation of vimentin expression in cultured human mammary epithelial cells.

Authors:  C Mørk; B van Deurs; O W Petersen
Journal:  Differentiation       Date:  1990-04       Impact factor: 3.880

10.  Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas.

Authors:  G Cattoretti; S Andreola; C Clemente; L D'Amato; F Rilke
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

View more
  13 in total

1.  Cytoskeletal and extracellular matrix proteins as markers for metastatic triple negative breast cancer.

Authors:  Mohammed Elimam Ahamed Mohammed; Nuha Mohammed Elhassan
Journal:  J Int Med Res       Date:  2019-10-11       Impact factor: 1.671

2.  Differentiation state and invasiveness of human breast cancer cell lines.

Authors:  C L Sommers; S W Byers; E W Thompson; J A Torri; E P Gelmann
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

3.  Tumour epithelial vimentin expression and outcome of pancreatic ductal adenocarcinomas.

Authors:  A Handra-Luca; S-M Hong; K Walter; C Wolfgang; R Hruban; M Goggins
Journal:  Br J Cancer       Date:  2011-03-29       Impact factor: 7.640

4.  Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366.

Authors:  Sara Caceres; Laura Peña; Paloma J de Andres; Maria J Illera; Mirtha S Lopez; Wendy A Woodward; James M Reuben; Juan C Illera
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

5.  Simultaneous knockdown of uPA and MMP9 can reduce breast cancer progression by increasing cell-cell adhesion and modulating EMT genes.

Authors:  Anuradha Moirangthem; Banashree Bondhopadhyay; Mala Mukherjee; Arghya Bandyopadhyay; Narendranath Mukherjee; Karabi Konar; Shubham Bhattacharya; Anupam Basu
Journal:  Sci Rep       Date:  2016-02-24       Impact factor: 4.379

6.  Does vimentin help to delineate the so-called 'basal type breast cancer'?

Authors:  Renata U Kusinska; Radzislaw Kordek; Elzbieta Pluciennik; Andrzej K Bednarek; Janusz H Piekarski; Piotr Potemski
Journal:  J Exp Clin Cancer Res       Date:  2009-08-20

7.  Comprehensive proteome quantification reveals NgBR as a new regulator for epithelial-mesenchymal transition of breast tumor cells.

Authors:  Baofeng Zhao; Bo Xu; Wenquan Hu; Chunxia Song; Fangjun Wang; Zhong Liu; Mingliang Ye; Hanfa Zou; Qing R Miao
Journal:  J Proteomics       Date:  2014-08-27       Impact factor: 4.044

8.  Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer.

Authors:  Su-Hyung Hong; David E Misek; Hong Wang; Eric Puravs; Robert Hinderer; Thomas J Giordano; Joel K Greenson; Dean E Brenner; Diane M Simeone; Craig D Logsdon; Samir M Hanash
Journal:  Biomark Insights       Date:  2006

9.  Are breast cancer molecular classes predictive of survival in patients with long follow-up?

Authors:  Danae Pracella; Serena Bonin; Renzo Barbazza; Anna Sapino; Isabella Castellano; Sandro Sulfaro; Giorgio Stanta
Journal:  Dis Markers       Date:  2013-10-30       Impact factor: 3.434

10.  TiHo-0906: a new feline mammary cancer cell line with molecular, morphological, and immunocytological characteristics of epithelial to mesenchymal transition.

Authors:  José Luis Granados-Soler; Johannes Junginger; Marion Hewicker-Trautwein; Kirsten Bornemann-Kolatzki; Julia Beck; Bertram Brenig; Daniela Betz; Jan Torben Schille; Hugo Murua Escobar; Ingo Nolte
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.